In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
about
Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection MethodsImpact of the New Delhi metallo-beta-lactamase on beta-lactam antibioticsA Flow Cytometric and Computational Approaches to Carbapenems Affinity to the Different Types of CarbapenemasesUnexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.Detection of OXA-48-type carbapenemase-producing Enterobacteriaceae in diagnostic laboratories can be enhanced by addition of bicarbonates to cultivation media or reaction buffers.Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial DominanceIn vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-β-lactamase (VIM).Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomesNew Delhi Metallo-Beta-Lactamase (NDM-1)-Producing Klebsiella Pneumoniae Isolated from a Burned Patient.Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo-β-lactamase (VIM) in a murine thigh infection model.Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.Recent advances in the understanding and management of Klebsiella pneumoniae.Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.
P2860
Q26744583-762C7A85-D4A3-43EE-85DC-7B4AFD60C3C2Q26783267-B24363CD-657D-4618-84B3-FFE4005758BEQ28831094-DEA0208D-229A-4077-B376-465E30B6F921Q34596918-BA6CBF8A-A679-43B0-8D1B-4ADDCF8FEC70Q35083616-CEC50EF6-6F38-4F6A-9DAB-086ECE9B4AF4Q36076066-8BF8BC7D-2770-4938-A8D6-974A9548DD30Q37097371-C2B81AF8-1163-4722-929D-B9D90B425BFCQ37501026-4D96DB2A-E918-47C4-BC41-1F78115342EFQ40131013-09D18F32-B6F0-499D-9F25-15316C0B7238Q40976243-7949AA51-7F1B-42FF-849F-F7F91AFF4E5AQ41987704-7522BC88-0C62-415D-A9AD-19A7CC5ED8F6Q42367237-D3394EAC-6E56-4CB7-ABAC-7271545B3BD6Q46152898-FBB3B5B2-92FB-4CB9-9680-F26EAD1478F7
P2860
In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo efficacy of human simu ...... -producing Enterobacteriaceae.
@en
In vivo efficacy of human simu ...... -producing Enterobacteriaceae.
@nl
type
label
In vivo efficacy of human simu ...... -producing Enterobacteriaceae.
@en
In vivo efficacy of human simu ...... -producing Enterobacteriaceae.
@nl
prefLabel
In vivo efficacy of human simu ...... -producing Enterobacteriaceae.
@en
In vivo efficacy of human simu ...... -producing Enterobacteriaceae.
@nl
P2093
P2860
P356
P1476
In vivo efficacy of human simu ...... -producing Enterobacteriaceae.
@en
P2093
David P Nicolau
Dora E Wiskirchen
Jared L Crandon
P2860
P304
P356
10.1128/AAC.01946-13
P407
P577
2013-12-30T00:00:00Z